EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Outcomes in patients with refractory/relapsed CNS lymphoma treated in complete remission: autologous transplantation vs. CAR-T therapy

Fan Yang, Rui Liu, Zhonghua Fu, Yuelu Guo, Lixia Ma, Miaomiao Cao, Biping Deng, Haifeng Wu, Chen Chen, Xiaoyan Ke, Kai Hu

Cancer Immunology, Immunotherapy · 2026

DOI: 10.1007/s00262-026-04334-x ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Fan Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lymphoma and Myeloma Research Center, GoBroad Hospital, Building 1, No.4 Science Park Road, Life Science Park, Changping District, Beij…. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Immunotherapy, Adoptive, Hematopoietic Stem Cell Transplantation, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Autologous hematopoietic cell transplantation (ASCT) is a reasonable consolidation therapy for eligible patients with chemosensitive relapsed central nervous system lymphoma (CNSL) who have achieved complete remission (CR) and maintained the CR. Chimeric antigen receptor T-cell (CAR-T) therapy is an effective treatment option for patients with relapsed CNSL, although evidence on outcomes in patients who achieve CR is limited. AIM: To compare the efficacy of ASCT versus CAR-T therapy as consolidation therapy in patients with relapsed CNSL once CR had been re-achieved. METHODS: A retrospective observational study was conducted on patients who underwent ASCT or CAR-T therapy at the Department of Lymphoma, Beijing Gobroad Hospital, between 2021 and 2024. CAR-T therapy was part of the clinical trial "Different B-cell-targeted CAR-T cells for relapsed/refractory CNSL (ChiCTR2200058972)". RESULTS: Sixty patients, including 42 (70%) with primary CNSL and 18 (30%) with diffuse large B-cell lymphoma (DLBCL) with secondary CNS involvement, were enrolled. The median follow-up duration was 12.1 months (1.28-59.9 months). Compared with patients in the CAR-T group, patients who received ASCT while in CR had superior progression-free survival (PFS) [3-year PFS 80% (95% CI: 48.4-93.4) vs. 64.8% (95% CI: 38.9-81.9); P = 0.026] and a lower cumulative incidence of relapse/progression [3-year relapse rate 20% (95% CI: 4.12-44.39) vs. 30.2% (95% CI: 11.0-52.2); P = 0.038]. CONCLUSION: Compared with CAR-T therapy, ASCT was associated with improved PFS in patients with relapsed CNSL who had achieved CR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Nervous System NeoplasmsImmunotherapy, AdoptiveHematopoietic Stem Cell TransplantationNeoplasm Recurrence, LocalHumansFemaleMaleMiddle AgedTransplantation, AutologousRetrospective StudiesAdultRemission InductionTreatment OutcomeAgedReceptors, Chimeric Antigen

Stichwörter der Autor:innen

Autologous transplantation (ASCT)Chimeric antigen receptor T-cell (CAR-T) therapyConsolidation therapyRefractory/relapsed central nervous system lymphoma (R/R CNSL)

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Lymphoma and Myeloma Research Center, GoBroad Hospital, Building 1, No.4 Science Park Road, Life Science Park, Changping District, Beijing, 102200, China.
  • Cytology Laboratory, Beijing GoBroad Boren Hospital, Jitong East Road No.6, Fengtai District, Beijing, 100070, China.
  • Department of Biostatistics, GoBroad Research Center, Leeza SOHO South Tower, Fengtai District, Beijing, 100073, China.
  • Department of Lymphoma and Myeloma Research Center, GoBroad Hospital, Building 1, No.4 Science Park Road, Life Science Park, Changping District, Beijing, 102200, China. huk@gobroadhealthcare.com.

Zitieren

APA

Yang, F., Liu, R., Fu, Z., Guo, Y., Ma, L., Cao, M., Deng, B., Wu, H., Chen, C., Ke, X., & Hu, K. (2026). Outcomes in patients with refractory/relapsed CNS lymphoma treated in complete remission: autologous transplantation vs. CAR-T therapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04334-x

Vancouver

Yang F, Liu R, Fu Z, Guo Y, Ma L, Cao M, et al. Outcomes in patients with refractory/relapsed CNS lymphoma treated in complete remission: autologous transplantation vs. CAR-T therapy. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04334-x

BibTeX
@article{Yang2026,
  author = {Yang, Fan and Liu, Rui and Fu, Zhonghua and Guo, Yuelu and Ma, Lixia and Cao, Miaomiao and Deng, Biping and Wu, Haifeng and Chen, Chen and Ke, Xiaoyan and Hu, Kai},
  title = {Outcomes in patients with refractory/relapsed CNS lymphoma treated in complete remission: autologous transplantation vs. CAR-T therapy},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04334-x}
}
Kostenlos starten →